SMMT - NASDAQ

Summit Therapeutics Inc.

SMMT·NASDAQ

$15.07

+1.4%

HealthcareBiotechnology

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$11.68B

EPS-1.4400

P/E Ratio-10.47

Earnings Date08/10/2026

751.18M

Assets

72%

3Y+13.0%

5Y+633.0%

10Y+1499.0%

92.32M

Total Liabilities

97%

3Y-83.0%

5Y+301.0%

10Y+80.0%

658.86M

Total Equity

69%

3Y+420.0%

5Y+729.0%

10Y-15190.0%

Summit Therapeutics Inc. Funding & Solvency Profile

SMMT · NASDAQ

Current Assets

Cash & Cash Equivalents225.27M

Net Receivables0.00

Inventory0.00

Other Current Assets6.85M

Total Current Assets720 M

Non-Current Assets

Property, Plant & Equipment21.68M

Goodwill & Intangible Assets2.00M

Long-Term Investments0.00

Other Non-Current Assets7.21M

Total Non-Current Assets29 M

Total Assets

751.18M

Financial Health Analysis

Current Ratio

9.87x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.14x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

647 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

96% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Summit Therapeutics Inc. Balance Sheet

SMMT • NASDAQ

Summit Therapeutics Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Jan 2019	Jan 2018	Jan 2017	Jan 2016	Jan 2015	Jan 2014	Jan 2013	Jan 2012	Jan 2011	Jan 2010	Jan 2009	Jan 2008	Jan 2007
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	225.3M	104.9M	71.4M	348.6M	71.8M	66.4M	50M	35.2M	28.5M	35.1M	23.2M	17M	3.3M	5.3M	3.3M	5.1M	9.7M	3.9M	20.1M	35.9M
Short-Term Investments	488.2M	307.5M	114.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	713.4M	412.3M	186.2M	348.6M	71.8M	66.4M	50M	35.2M	28.5M	35.1M	23.2M	17M	3.3M	5.3M	3.3M	5.1M	9.7M	3.9M	20.1M	35.9M
Net Receivables	0.0	557K	848K	6.1M	8.6M	10.2M	5.3M	7.9M	11.1M	0.0	2.3M	0.0	0.0	375.9K	343.9K	492.2K	677.4K	1M	1.5M	1.3M
Accounts Receivables	0.0	0.0	0.0	349K	1.5M	331K	408.4K	2.2M	11.1M	0.0	2.3M	0.0	0.0	80.6K	73.8K	50.6K	65.5K	938.3K	375.8K	555.1K
Other Receivables	0.0	557K	848K	5.8M	7.2M	9.9M	0.0	5.8M	0.0	0.0	0.0	0.0	0.0	295.4K	270.1K	441.5K	611.9K	111.4K	1.1M	710.1K
Inventory	0.0	0.0	0.0	0.0	0.0	-11.7M	1.0	0.0	0.0	110.6K	563.1K	4.2M	0.0	0.0	0.0	0.0	0.0	564K	670.1K	369.4K
Prepaids	0.0	0.0	2.4M	1.5M	7.2M	0.0	0.0	9.7M	6.5M	856.2K	1.7M	4M	569.1K	352.2K	116.2K	269K	204.5K	1.1M	1.7M	233.4K
Other Current Assets	6.9M	10.8M	181K	300.5M	9.7M	1.5M	6.9M	8.3M	15.8M	4.6M	4.7M	1.3M	1.2M	541.8K	430.3K	0.0	1.0	1.2M	1.4M	2M
Total Current Assets	720.3M	423.8M	189.7M	656.7M	97.3M	66.4M	62.1M	61.3M	50.8M	41.7M	29.7M	22.9M	5.1M	6.6M	4.2M	5.9M	10.6M	7.8M	25.3M	38.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	21.7M	7.4M	6.1M	5.1M	3.5M	1.3M	1.2M	807.9K	1.1M	145K	118.2K	82.9K	70.9K	36.3K	234K	411.5K	535.2K	5.4M	8.5M	5.1M
Goodwill	2M	1.9M	1.9M	1.8M	2M	2M	1.9M	2.4M	3.5M	830K	945.7K	1M	664K	0.0	0.0	0.0	0.0	0.0	19.4M	0.0
Intangible Assets	0.0	0.0	0.0	0.0	10.4M	11.5M	7.7M	13.9M	20.9M	4.3M	4.9M	5.2M	3.5M	270.1K	1.7M	1.7M	7.2M	6.9M	16.2M	2.9M
Goodwill & Intangible Assets	2M	1.9M	1.9M	1.8M	12.4M	13.5M	8.9M	16.3M	24.4M	5.2M	5.9M	6.2M	4.2M	270.1K	1.7M	1.7M	7.2M	6.9M	35.6M	2.9M
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3M	5.1M	9.7M	3.9M	20.1M	35.9M
Other Non-Current Assets	7.2M	2.5M	5.3M	577K	170K	21.3M	3.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.3M	-5.1M	-9.7M	-3.9M	-20.1M	-35.9M
Total Non-Current Assets	30.9M	11.8M	13.2M	7.5M	16.1M	36.1M	13.3M	17.1M	25.6M	5.3M	6M	6.3M	5.8M	306.4K	2M	2.2M	7.8M	12.3M	44.1M	8M
Total Assets	751.2M	435.6M	202.9M	664.2M	113.4M	102.5M	75.5M	78.4M	76.4M	47M	35.7M	29.2M	10.9M	6.9M	6.1M	8.1M	18.4M	20.1M	69.4M	46.4M
LIABILITIES
CURRENT LIABILITIES
Total Payables	20.3M	4.6M	2.7M	355K	4.4M	6.1M	3.4M	6.3M	12.5M	1.4M	1.3M	5.4M	725.8K	597.1K	738K	838.7K	351.5K	1.7M	3.9M	2.5M
Accounts Payable	20.3M	4.6M	2.7M	355K	4.4M	6.1M	2.6M	5.8M	12.5M	1.1M	1M	5.4M	575.7K	401.2K	584.2K	525.4K	238K	972.9K	3.6M	2.3M
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	456.4K	0.0	242.5K	256.4K	0.0	300.2K	195.9K	153.9K	313.3K	113.4K	719.2K	266.5K	196.2K
Accrued Expenses	32.1M	0.0	5.4M	10.7M	11.3M	3.3M	4.3M	0.0	0.0	2.9M	0.0	0.0	0.0	998K	0.0	0.0	0.0	0.0	0.0	0.0
Short Term Debt	0.0	0.0	0.0	19.8M	284.2K	0.0	632.6K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	194.6K	373.8K	129.5K
Capital Lease Obligations (Current)	3.4M	3.8M	2.8M	1.7M	1.1M	390K	355.6K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	249.2K	232.1K	117.5K	112.5K	91.9K	92.4K	110.6K	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	7.9M	8.4M	1.2M	0.0	-18M	8.6M	0.0	0.0	0.0	924K	0.0	0.0	0.0	-1.5M	-2.8M	-453.1K
Other Current Liabilities	17.2M	33.3M	9.5M	6.3M	641.2K	1.7M	2.4M	10.6M	20M	6.6M	3.3M	295.3K	2.4M	-69.1K	1.3M	1.1M	1.4M	804.2K	2.5M	257K
Total Current Liabilities	73M	41.7M	20.4M	38.8M	25.6M	19.9M	9.9M	16.9M	26.8M	13.6M	4.6M	5.7M	3.1M	2.4M	2M	1.9M	1.8M	2.7M	6.6M	2.8M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	100M	494.5M	0.0	0.0	0.0	0.0	-17.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7M	2.4M	1.2M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	569K	385.9K	1.1M	25.5M	29.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	192.9K	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	1.6M	2.2M	3.4M	706.2K	945.7K	1M	0.0	0.0	0.0	0.0	1.5M	1.5M	3.7M	0.0
Other Non-Current Liabilities	1.8M	1.6M	1.6M	1.4M	2.8M	2.5M	2.2M	3.3M	5.7M	-39.9K	7.3M	0.0	0.0	0.0	321.9K	324.4K	1.9M	1.9M	2.3M	2.3M
Total Non-Current Liabilities	19.3M	5.1M	104.9M	498.7M	4.5M	3.2M	4.4M	5.7M	35.6M	37.7M	1M	1M	0.0	0.0	321.9K	324.4K	3.4M	5.1M	8.7M	3.5M
Capital Lease Obligations	20.9M	7.2M	6.1M	4.5M	2.8M	465K	330.2K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	92.3M	46.8M	125.3M	537.5M	30.1M	23M	14.3M	22.6M	62.4M	51.3M	5.6M	6.7M	3.1M	2.4M	2.3M	2.2M	5.2M	7.8M	15.3M	6.3M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6M	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	3.8M	0.0	0.0	0.0	1.0	29.1M	1.7M	28.6M	19.9M	16.1M	0.0	0.0	0.0	0.0	0.0
Common Stock	7.8M	7.4M	7M	2.1M	980K	826K	3.5M	2.1M	1M	772.5K	873K	619.3K	16.6M	13.9M	11.2M	11M	11M	8.1M	12.7M	7.3M
Additional Paid-In Capital	2.9B	1.6B	1.1B	504.8M	384M	214.5M	182.1M	121.7M	60.2M	46.4M	46M	24.1M	40.2M	33.7M	48.4M	46.9M	47.3M	37.2M	45.2M	43.8M
Retained Earnings	-2.3B	-1.2B	-993.3M	-378.3M	-299.5M	-214.7M	-97.6M	-99.8M	-114.5M	-92.2M	-67.4M	-45.6M	-74.5M	-61.7M	-54.7M	-50.9M	-43.9M	-52.8M	-28.3M	-8.1M
Accumulated Other Comprehensive Income/Loss	-2.5M	-2.3M	-2.4M	-1.9M	-2.2M	-3.8M	22M	0.0	0.0	25.7M	27.3M	-3.2M	-3.2M	-3.1M	-1.7M	-1.6M	-5.2M	-3.2M	-2.5M	-918K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	-61.0	78.8M	19.7M	31.8M	86.7M	41.4M	58.1M	50.3M	40.6M	32.1M	10M	481.1K	4M	23.1M	26.9M	-2M
Total Stockholders' Equity	658.9M	388.7M	77.7M	126.7M	83.3M	79.5M	61.1M	55.8M	14M	-4.4M	30.1M	22.5M	7.9M	4.5M	3.8M	5.8M	13.2M	12.3M	54.1M	40.1M
Total Equity	658.9M	388.7M	77.7M	126.7M	83.3M	79.5M	61.1M	55.8M	14M	-4.4M	30.1M	22.5M	7.9M	4.5M	3.8M	5.8M	13.2M	12.3M	54.1M	40.1M
SUMMARY
Total Liabilities & Equity	751.2M	435.6M	202.9M	664.2M	113.4M	102.5M	75.5M	78.4M	76.4M	47M	35.7M	29.2M	10.9M	6.9M	6.1M	8.1M	18.4M	20.1M	69.4M	46.4M
Total Investments	488.2M	307.5M	114.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0
Total Debt	20.9M	7.2M	106.1M	518.8M	2.8M	465K	699.6K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9M	2.8M	1.3M
Net Debt	-204.4M	-97.6M	34.7M	170.2M	-69M	-66M	-49.3M	-35.2M	-28.5M	-35.1M	-23.2M	-17M	-3.3M	-5.3M	-3.3M	-5.1M	-9.7M	-2M	-17.3M	-34.6M
Shares Outstanding	744,442,538	744,442,538	744,442,538	744,442,538	744,442,538	744,442,538	744,442,538	744,442,538	744,442,538	744,442,538	744,442,538	744,442,538	744,442,538	744,442,538	744,442,538	744,442,538	744,442,538	744,442,538	744,442,538	744,442,538

SEC Filings

SMMT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 03, 2026	June 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	June 01, 2026	May 30, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	April 30, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 17, 2026	April 17, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 23, 2026	February 23, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 23, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 29, 2026	January 29, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 07, 2025	November 07, 2025	2025	View Filing

Showing 1 to 10 of 275 filings

Related Guides

Blog Categories

Continue your SMMT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.